Estrella Immunopharma (ESLA) announced that the company has regained compliance with the listing requirements of Nasdaq. This confirmation follows the company’s efforts to improve its balance sheet, including raising new capital to continue development of its therapeutic candidates.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESLA: